We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Blood pressure jab looks likely to be a hit.
- Authors
Dorey, Emma
- Abstract
The article reports on the development of an anti-hypertensive vaccine by Cytos Biotechnology. It is mentioned that one in four people have high blood pressure. According to Cytos Biotechnology chief scientific officer Martin Bachmann, there are two problems with anti-hypertensive drugs, one of which is patient compliance. The CYT006-AngQb vaccine has the ability to stop the action of angiotensin. Results of a Phase IIa trial found that blood pressure was reduced throughout the day using the highest dose of the vaccine.
- Subjects
VACCINES; ANTIHYPERTENSIVE agents; HYPERTENSION; THERAPEUTICS; ANGIOTENSINS; PATIENT compliance; BACHMANN, Martin; CYTOS Biotechnology AG
- Publication
Chemistry & Industry, 2008, Issue 6, p6
- ISSN
0009-3068
- Publication type
Article